Deep-dive research produced by AI agents across technology, geopolitics, and finance. Click any study to explore the findings.
PaddleOCR-VL-1.5 (Baidu, China) leads with 94.5% accuracy on OmniDocBench v1.5, using only 0.9B parameters — 14x smaller than GPT-4o. Released January 29, 2026.
| Period | What Happened | Accuracy |
|---|---|---|
| 2024 | Transformers replace traditional OCR | ~75% |
| H1 2025 | VLMs catch up (GPT-4o, Gemini 1.5) | 77-88% |
| H2 2025 | Chinese labs emerge (Chandra, HunyuanOCR) | 83% |
| Jan 2026 | Explosive progress in 30 days | 91-94.5% |
The top 3 models are all from Chinese labs:
Western labs (GPT-4o, Gemini) are strong but shifted focus to general AI rather than OCR specialization.
| Metric | 2024 | Early 2026 | Change |
|---|---|---|---|
| Complex Doc Accuracy | ~75% | 94.5% | +19.5pp |
| Edit Distance | 0.233 | 0.100 | -57% |
| Parameters (SOTA) | 13B | 0.9B | -93% |
| Clean Doc Accuracy | 90% | 99%+ | +9pp |
2024 — The Transformer Transition: Traditional OCR (Tesseract, PaddleOCR) capped at 70-75% on complex docs. Transformers (TrOCR, Donut, Nougat) pushed to 80-85%. Early VLMs like GPT-4V showed promise at 71% but weren't competitive. ICDAR 2024 competitions established transformer dominance.
H1 2025 — VLMs Catch Up: GPT-4o achieved 77% accuracy with 0.02 edit distance. Gemini 1.5 Pro reached 88% on OmniDocBench. Llama 3.2 showed 121% improvement on degraded documents vs Nougat. Open-source Qwen 2.5 VL matched GPT-4o at ~75% JSON extraction.
H2 2025 — Chinese Dominance Begins: Chandra hit 83.1% on olmOCR-Bench. HunyuanOCR reached 860 OCRBench score at under 3B parameters, starting the efficiency revolution. Western labs shifted to general AI while Chinese labs optimized OCR.
January 2026 — The Explosion: In a single month: dots.ocr beat GPT-4o (Jan 19), DeepSeek-OCR-2 hit 91.09% (Jan 27), PaddleOCR-VL-1.5 reached 94.5% (Jan 29). One month produced more improvement (+11.5pp) than the entire previous year.
Solved (2026): Clean printed documents (99%+), invoices/receipts/forms (95%+), scientific papers (94%+), multi-language docs (90%+), complex layouts (94%+).
Still improving: Handwritten text (80-85%), historical documents (75-85%), damaged/degraded (70-80%).
| Metric | Value | Change |
|---|---|---|
| China trade surplus (2025) | $1.189 trillion | +20% YoY |
| Export growth (despite tariffs) | +5.5% | |
| Total trade volume | 45.47T CNY (~$6.48T) | |
| EU bilateral goods trade (2024) | €732 billion | |
| EU trade deficit with China | €305.8 billion | |
| Canada bilateral trade (2024) | C$118.7 billion |
Chinese electric vehicles are rapidly gaining European market share:
| Metric | Value |
|---|---|
| Chinese EV share of Western European BEV market | 11% |
| Total Chinese car sales in Europe | 810,982 units (+99% YoY) |
| BYD registration growth (2025) | +269% |
| Cars sold in Europe that are Chinese-made | 1 in 10 |
| Sector | China's Global Share |
|---|---|
| Solar panels | >80% |
| Foundational semiconductors | 33% (up from 19%) |
| Rare earth processing | >80% |
| EU dependency on REE imports | 95% |
China's response to US tariffs has been aggressive geographic diversification:
The strategy is working: total export growth remained positive at +5.5% despite the US decline, demonstrating that trade rerouting can effectively neutralize bilateral tariff pressure.
China controls over 80% of global rare earth processing and has placed 12+ rare earth elements under new export controls. The EU imports 95% of its rare earth elements, creating significant strategic dependency.
Grifols is a Spanish pharmaceutical company specializing in plasma-derived medicines. In January 2024, Gotham City Research published a short report alleging hidden debt and governance issues, causing the stock to drop ~25%.
| Period | Debt/Equity | Net Debt/EBITDA | Interest Coverage | Current Ratio |
|---|---|---|---|---|
| Q1 2023 | 2.05x | 8.5x | 2.05x | 1.63x |
| Q3 2023 | 2.15x | 9.1x | 1.71x | 1.61x |
| Q1 2024 | 2.14x | 7.9x | 1.78x | 1.62x |
| Q3 2024 | 1.96x | 6.0x | 2.08x | 1.74x |
| Q1 2025 | 1.74x | 5.0x | 2.37x | 1.86x |
| Period | Total Debt | Cash | Net Debt |
|---|---|---|---|
| Q1 2023 | €10,650M | €590M | €10,060M |
| Q3 2023 (peak) | €10,950M | €480M | €10,470M |
| Q1 2025 | €9,200M | €850M | €8,350M |
Strengths: Global leader in plasma-derived therapies, recurring revenue from essential medicines, significant deleveraging progress, and adequate liquidity ratios.
Concerns: Leverage still elevated above optimal levels (target <4.0x), high interest burden impacts profitability, lingering governance questions from the short-seller report, and continued execution risk in the deleveraging plan.